SCHEMBL829425

SCHEMBL829425

O=C(Oc1cc(Cl)c(Cl)cc1Cl)N1CCN(c2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.56
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ALOX15 P16050 1/20 0.52
ALDH1A1 P00352 6/20 0.51
TSHR P16473 4/20 0.51
MEN1 O00255 3/20 0.51
USP2 O75604 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPK1 P28482 3/20 0.51
HTT P42858 1/20 0.51
HSP90AA1 P07900 1/20 0.50
LMNA P02545 4/20 0.49
GAA P10253 1/20 0.49
TP53 P04637 3/20 0.49
CYP3A4 P08684 1/20 0.49
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829665 0.81 FAAH (0.53) FAAHMAPTSMN1; SMN2ALOX15ALDH1A1
SCHEMBL828934 0.79 MAPT (0.55) MAPTSMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL829543 0.78 MAPT (0.46) MAPTSMN1; SMN2ALOX15ALDH1A1TSHR
SCHEMBL830223 0.77 TDP1 (0.57) MAPTSMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL9460982 0.76 ALOX15 (0.57) FAAHMAPTSMN1; SMN2ALOX15ALDH1A1
SCHEMBL829875 0.76 CYP2C9 (0.60) FAAHSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL829346 0.74 HPGD (0.57) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6790884 0.74 MGLL (0.63) MAPTSMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL829898 0.72 GAA (0.54) MAPTSMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL8844981 0.72 ALOX15 (0.72) FAAHMAPTSMN1; SMN2ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 FAAH 3046/4885MAPT 3311/4885SMN1; SMN2 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.